![]() ![]() Disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia.Intralipid is contraindicated in patients with: Intralipid ® 30% Pharmacy Bulk Package is indicated for use in a pharmacy admixture program for the preparation of three-in-one or total nutrient admixtures (TNAs) to provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of EFAD. Intralipid will prevent the biochemical lesions of essential fatty acid deficiency (EFAD) and correct the clinical manifestations of the EFAD syndrome. The infused fat particles are cleared from the blood stream in a manner thought to be comparable to the clearing of chylomicrons. ![]() Intralipid is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary. The container-emulsion unit is a closed system and is not dependent upon entry of external air during administration. The container is nontoxic and biologically inert. This product is not made with natural rubber latex. The container does not contain DEHP (di(2-ethylhexyl) phthalate) or PVC. ![]() It contains no plasticizers and exhibits virtually no leachables. The film is polypropylene based comprising three co-extruded layers. The primary plastic container (Biofine TM) is made from multilayered film specifically designed for parenteral nutrition drug products. The phospholipids present contribute 47 milligrams or approximately 1.5 mmol of phosphorus per 100 mL of the emulsion. The total caloric value, including fat, phospholipid and glycerin, is 3.0 kcal per mL of Intralipid 30%. Fat Emulsion) has an osmolality of approximately 310 mOsmoL/kg water (which represents 200 mOsmoL/L of emulsion) and contains emulsified fat particles of approximately 0.5 micron size. SMOFlipids children lipid emulsion lipid overload syndrome parenteral nutrition.Glycerin is chemically designated C 3 H 8 O 3 and is a clear colorless, hygroscopic syrupy liquid. To the best of our knowledge, this is the first case of fat overload syndrome caused by SMOFlipid emulsion described in the literature. In the next couple of days, she received extra platelets, erythrocyte transfusion, and filgrastim (Neupogen 5 µg/kg/d) due to a very low leukocyte count. The patient was successfully treated with supportive care combining fluid infusion, transfusion of platelets, and substitution of serum albumin (0.5 g/kg/d) and fresh-frozen plasma (10 mL/kg). Fat overload syndrome occurred as a result of accidental, very rapid infusion of a 20% soy oil, medium-chain triglyceride, olive and fish oil-based lipid emulsion (SMOFlipid) that showed the same complications seen with an earlier lipid emulsion (Intralipid). We report fat overload syndrome in a 2-year-old girl with short bowel syndrome on home parenteral nutrition. Several reports in the literature describe fat overload syndrome caused by rapid infusion of lipid emulsions, all with soybean-based lipid emulsions. Other symptoms include anemia, leukopenia, thrombocytopenia, low fibrinogen levels, and coagulopathy. It is characterized by headaches, fever, jaundice, hepatosplenomegaly, respiratory distress, and spontaneous hemorrhage. Fat overload syndrome is a well-known complication of intravenous lipid emulsion therapy. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |